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1684-1182/Copyright ª 2015, TaiwanAbstract Background/Purpose: House dust mite (HDM) is well known as one of the major in-
door allergens that trigger allergic inflammation, especially asthma, and accounts for 85% of all
cases. So far, asthma has been thought of as a condition of imbalance between T helper (Th)1
and Th2. Fungal immunomodulatory protein-Flammulina velutipes (FIP-fve) has been seem-
ingly demonstrated to modulate the response to Th1 cytokine production. The aim of this study
was to investigate if the oral administration of FIP-fve can inhibit HDM-induced asthma inflam-
mation in the mouse model.
Methods: We divided the mice (female BALB/c, 4e6 weeks) into four groups: the prevention
group, which consisted of mice sensitized by HDM (intraperitoneally on Day 1, Day 7, and
Day 14, and intranasally on Day 14, Day 17, Day 21, Day 24, and Day 27) fed with FIP-fve from
Day 1 to Day 14; the treatment group, which comprised mice that received treatment from Day
14 to Day 28; the positive control (PC, sensitized by HDM fed without FIP-fve) group; and the
negative control group (NC, nonsensitized). Airway hyperresponsiveness induced byllergy, Asthma and Rheumatology, Department of Pediatrics, Chung Shan Medical University Hospital,
rth Road, Taichung 402, Taiwan, ROC.
.tw, kohuang.lue@gmail.com (K.-H. Lue).
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and Infection (2015), http://dx.doi.omethacholine challenge was determined using whole-body barometric plethysmography. In
addition, cytokines were analyzed from bronchoalveolar lavage fluid and serum. Histopatho-
logical studies and Liu’s staining method in mice lungs were also performed.
Results: The results showed that both pre- and posttreated FIP-fve groups had significantly
reduced airway hyperresponsiveness compared with the PC group after methacholine chal-
lenge. In addition, a significantly decreased level of HDM-specific immunoglobulin E in serum
and decreased production of Th2 cytokines in bronchoalveolar lavage fluid and serum were
observed in these two FIP-fve fed groups. Moreover, more decreased amounts of infiltrating in-
flammatory cells were present in the lungs of FIP-fve fed groups than those of the PC group.
Conclusion: Oral FIP-fve had an anti-inflammatory effect on the acute phase of the airway in-
flammatory process induced by HDM in the mouse model and might have a potentially thera-
peutic role for allergic airway diseases.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Asthma is one of the most common chronic inflammatory
diseases and affects > 300 million people worldwide. The
inhalation of allergens stimulate the innate immune system
to secrete cytokines that promote antigen expressions on
CD4þ T cells, and activate the antigen-presenting cells and
T cells to manufacture T helper (Th2) responses.1 Th2 cy-
tokines, including interleukin (IL)-4, IL-5, IL-9, and IL-13,
induce the conversions in the pulmonary parenchyma and
airways that are associated with asthma, the manifesta-
tions with complexities of airway eosinophilia, mastocy-
tosis, pulmonary lymphocytosis, alternative macrophage
activation, epithelial cell proliferation with goblet cell
hyperplasia, and increased mucus secretion. Additionally,
hyperplasia, hypertrophy, hypercontractility, and sub-
epithelial fibrosis of smooth muscle, immunoglobulin E (IgE)
hypersecretion, increased production of chemokines that
attract T cells, eosinophils, neutrophils, mast cells, or their
precursors to the lungs, and airway hyperresponsiveness
(AHR) are some of the asthmatic manifestations attributed
to Th2 cytokines as well.2
House dust mite (HDM) is a predominant source of al-
lergens, resulting in a population of atopic symptoms in 10%
of individuals.3 Specifically, the species Dermatophagoides
pteronyssinus (Der p) is the most recurrent source of HDM-
related allergens that induce respiratory allergy. The
allergenic potential of HDM relies not only on the HDMs
themselves but also on their fecal pellets.4e9 Allergens
belong to protein families with diverse biological functions
that contribute to allergenicity, as indicated by the prote-
ase activity of mite group 1 allergens Der p 1 and Der f 1
(Dermatophagoides farina) and the interaction with the
innate immune system by the allergenic mite group 2 al-
lergens Der p 2 and Der f 2.10,11 After inhalation of HDM,
lung bronchial epithelial cells direct the dendritic cells,
which form a dense filling in the airways to polarize Th2
immunogenicity via the release of innate pro-Th2
cytokines.
Interferon-gamma (IFN-g) is known to be produced by
Th1 cells and to have the ability to inhibit Th2 cell prolif-
eration, IgE production, and further increase Th1hu P-Y, et al., Oral fungal immun
tential treatment for allergic airw
rg/10.1016/j.jmii.2015.07.013differentiation by inducing IL-12 receptor b2-chain ex-
pressions on T cells and IL-12 production by macrophages.12
By contrast, IL-4, IL-6, and IL-10 produced by Th2 cells can
further promote Th2 differentiation and inhibit macro-
phage antigen expression and IL-12 production. However,
recent studies suggested that an array of proinflammatory
mediators contributes to both the acute and chronic in-
flammations associated with asthma.13e15
Golden needle mushroom is a kind of popular edible
mushroom in Asia. A novel fungal immunomodulatory pro-
tein (FIP-fve) has been isolated and purified from the edible
golden needle mushroom (Flammulina velutipes). FIP-fve is
a protein that consists of 114 amino acid residues with a
molecular weight of 13 kDa.16e20 A previous study had
shown that FIP-fve stimulated the proliferation of human
peripheral blood mononuclear cells in vitro with increased
transcription of IL-2 and IFN-g. Intraperitoneal (I.P.) in-
jections of FIP-fve appeared to modify immune responses in
mice and inhibit anaphylactic responses in some previous
studies.17,19
In our previous study, we investigated the impact of FIP-
fve treatment in mice with preexposure to ovalbumin (OVA)
on the generation of allergic-inflammatory responses.21 We
hypothesized that orally administrated FIP-fve should be
able to switch the immune response toward Th1 and Treg
response. To prove this hypothesis in a more realistic basis,
the mouse model experiment using the same treatment
(oral FIP-fve) as in the previous study was evaluated for the
effectiveness of FIP-fve in mice subjected to HDM sensiti-
zation/challenge.Methods
HDM preparation
HDM was isolated from 0.2 g HDM fecal pellets (Der p;
Allergon AB, A¨ngelholm, Sweden; HDM stands for Der p in
the following context) by first dissolving fecal pellets in
4 mL phosphate-buffered saline (PBS); then, after adding
8 mL ethyl ether, the solution was mixed by vortex. The
crude extract was formed as pellets after centrifugationomodulatory protein-Flammulina velutipes has influence on pul-
ay disease: A mouse model, Journal of Microbiology, Immunology
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for drying out at 80C in a refrigerator for 3 days. After
gently mixing with 4 mL ddH2O, the HDM was harvested by
centrifugation in the form of supernatant. The Protein
Assay Dye (Bio-Rad, Hercules, California, USA) was used to
quantity the concentration of HDM.
FIP-fve purification
FIP-fve was purified from the raw extract of F. velutipes by
ion-exchange column chromatography as described in pre-
vious reports.17,18 In brief, the golden needle mushrooms
(150 g) were homogenized after adding 1 L ddH2O with 5%
acetic acid in 0.05M 2-mercaptoethanol on ice. The solution
was centrifuged (9820 g, 20 minutes, 4C), and the su-
pernatant was precipitated by adding the ammonium sul-
fate gently to saturation. The saturated solution was
centrifuged and then dialyzed with 10mM Tris/HCl for 48
hours at 4C with three replacements of the dialyzed so-
lution. The dialysate was performed in a diethylaminoethyl
cellulose (DE-52) column, which was equilibrated with
10mM Tris/HCl (pH 8.0). The column was washed with
200 mL equilibration buffer and then eluted with 200 mLFigure 1. Experimental mice were categorized into four group
intraperitoneal (I.P.) injection and challenged by 50 mL HDM solutio
normal control group (NC). (A) Mice (NC group) were sensitized an
jections. (B) The mice in this group represent the mouse model o
ulatory protein-Flammulina velutipes [FIP-fve; positive control (PC)
allergic asthma with pretreatment of FIP-fve and posttreatment
hyperresponsiveness; PBS Z phosphate-buffered saline.
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single peak on absorbance at 280 nm were collected. The
FIP-fve protein was present as a single band on sodium
dodecyl sulfate-polyacrylamide gel electrophoresis at
13 kDa. The activity of FIP-fve was examined with a pro-
liferation assay on human peripheral blood lymphocytes.
The active fractions were collected, with about 50 mg pu-
rified FIP-fve normally being obtained.17,18
Mice
Female BALB/c mice (5e8 weeks old) were purchased from
the National Laboratory Animal Center (Taipei, Taiwan). All
animal studies were approved by the Ethics Commission of
Chung Shan Medical University, Taichung, Taiwan. The mice
were handled as previously described.21 In brief, the mice
were housed in stainless cages with sufficient diet and
water under a 12-hour light/dark cycle. The experimental
mice were divided into four groups: (1) the normal control
group was treated with 50 mL PBS via I.P. injection and then
via the intranasal route (I.N.); (2) the positive control group
was sensitized by 50 mg HDM plus 50 mL PBS via I.P. injection
and then via the I.N. route; and (3) the pre- and (4) post-FIPs sensitized with 50 mg house dust mite (HDM) plus PBS by
n plus PBS by the intranasal route (I.N.) individually except the
d challenged with PBS equivalent to HDM via I.P. and I.N. in-
f allergic asthma without treatment using fungal immunomod-
]. (C and D) These groups of mice represent the mouse model of
of FIP-fve separately (Pre- and Post-FIP-fve). AHR Z airway
omodulatory protein-Flammulina velutipes has influence on pul-
ay disease: A mouse model, Journal of Microbiology, Immunology
Figure 2. The female BALB/c mice remained normal saline (NC) or were sensitized/challenged with HDM  treatment with FIP-
fve (200 mg/mouse) during the challenge phase. The airway hyperresponsiveness (AHR) to methacholine was assessed in unre-
strained mice using whole-body barometric plethysmography (Model PLY 3211; Buxco Electronic Inc., Sharon, CT, USA) to record
enhanced pauses (Penh). Each bar represents the mean  SEM of the Penh value from individual mice. *p < 0.05. **p < 0.01. FIP-
fveZ fungal immunomodulatory protein-Flammulina velutipes; HDMZ house dust mite; NCZ negative control; SEMZ standard
error of the mean.
Figure 3. The bronchoalveolar lavage fluid (BALF) was obtained from the normal control group and HDM sensitized/challenged
mice in the absence or presence of FIP-fve treatment. (A) The total cells and (BeD) inflammatory cells were counted (104) from the
BALF (in millimeters) by the morphometric evaluations of cytospin preparations. There seemed to be a trend toward decreasing
numbers of cells after pre- and posttreatment with FIP-fve from BALF, whether total numbers or eosinophiles and lymphocytes
(AeC). (D) However, monocytes were increased after treatment with FIP-fve, although there was no significant difference in the
pretreated group. The results are presented as means  SEM. *p < 0.05. **p < 0.01. ***p < 0.001. FIP-fve Z fungal immuno-
modulatory protein-Flammulina velutipes; HDM Z house dust mite; SEM Z standard error of the mean.
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injection and then via the I.N. route, and in addition, were
fed 200 mg of FIP-fve according to the protocol described in
the following subsection.Mouse model of allergic asthma
Three groups of mice were sensitized intraperitoneally by
50 mg of HDM extracted plus PBS on Day 1, Day 7, and Day
14, and followed by a series of challenges (I.N.) of 50 mg
HDM extracted plus PBS on Day 14, Day 17, Day 21, Day 24,
and Day 27, as previously described,21 as the mouse model
of allergic asthma. Among the three groups, one groupFigure 4. (A) Immunoglobulin E (IgE) and (B) immunoglobulin
G2a (IgG2a) in different concentrations were obtained from the
normal control group and theHDM sensitized/challengedmice in
the absence or presence FIP-fve treatment. (A) IgE concentra-
tion was significantly increased after the mice were sensitized
with HDM and significantly decreased after treatment with FIP-
fve. (B) IgG2a concentration was significantly increased in the
PC group compared to the NC group and significantly increased
after the mice were treated with FIP-fve compared to the PC
group. The results are presented as means  SEM. **p < 0.01.
***p < 0.001. FIP-fve Z fungal immunomodulatory protein-
Flammulina velutipes; HDM Z house dust mite; PC Z positive
control; SEMZ standard error of the mean.
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14 (the pretreated FIP-fve group of mice), another group
received FIP-fve 200 mg from Day 14 to Day 28 (the post-
treated FIP-fve group of mice), and the other group did not
receive FIP-fve (PC group of mice). The protocol is depicted
in Figure 1.
Measurement of AHR
AHR in response to different doses (0 mg/mL, 5 mg/mL,
10 mg/mL, and 20 mg/mL) of methacholine challenge was
measured with whole-body barometric plethysmography
(Model PLY 3211; Buxco Electronic Inc., Sharon, CT, USA) to
record the enhanced pauses (Penh), which was calculated
during the expiration and inspiration phases, as previously
described.21 The value of Pehn was calculated as follows:
Pehn Z Pause  peak expiratory pressure (PEP)/peak
inspiratory pressure (PIP). (1)
The Pehn values were averaged and reported as the base-
line values in percentage.20,22
Collection and measurement of bronchoalveolar
lavage fluid
Bronchoalveolar lavage fluid (BALF) was collected in 1 mL
PBS. The cellularity of BALF was examined using the he-
mocytometer. Differential cell counts were performed
after cytospinning onto slides with Liu’s staining. The
classification was according to standard morphologic
criteria, by 200e300 cells per slide. The supernatants of
BALF were collected and stored at 80C for subsequent
cytokine measurement.
Histological analysis
Samples of lung tissues were fixed in 10% formalin and were
embedded in paraffin, and 5-mm-thick sections were
stained with hematoxylin and eosin for further pathological
analysis.
Measurement of cytokines
The production of IL-4, IL-5, IL-10, IL-12, IL-13, trans-
forming growth factor beta (TGF-b), and IFN-g in serum and
BALF was quantified using Quantikine enzyme-linked
immunosorbent assay plates (ELISA) kit from R&D System
(Minneapolis, MN, USA), and the ELISA plates were read at
450 nm using the Bio-Rad ELISA reader.
Measurement of HDM-specific antibodies in serum
The levels of HDM-specific IgE and immunoglobulin G2a
(IgG2a) in serum were determined. In brief, the 96-well
microtiter plates were coated with 100 mg/mL of HDM in
0.1M NaHCO3 at 4C overnight. The plates were washed and
then blocked with 3% bovine serum albumin for 1 hour at
37C. After washing, 50 mL serially diluted sera in 3% bovine
serum albumin was added, and the mixture was incubated
overnight at 4C. After washing, Horseradish Peroxidaseomodulatory protein-Flammulina velutipes has influence on pul-
ay disease: A mouse model, Journal of Microbiology, Immunology
6 P.-Y. Chu et al.
+ MODEL
Please cite this article in press as: Chu P-Y, et al., Oral fungal immunomodulatory protein-Flammulina velutipes has influence on pul-
monary inflammatory process and potential treatment for allergic airway disease: A mouse model, Journal of Microbiology, Immunology
and Infection (2015), http://dx.doi.org/10.1016/j.jmii.2015.07.013
Figure 5. (continued).
FIP-fve suppresses HDM-induced airway inflammation 7
+ MODEL(HRP) was conjugated with the antimouse isotype-specific
antibody (BD Pharmingen, Franklin Lakes, New Jersey,
USA), and optimal dilutions were added. The plates were
incubated at 37C for 2 hours and were then washed. To
determine the IgE/IgG2a, p-nitrophenyl phosphate sub-
strate (Sigma Chemical Co., St Louis, MO, USA) was added
and the absorbance at 490 nm was measured.
Statistical analysis
All data points represent the mean  standard error of the
mean of the individual mice groups. Analyses were per-
formed using the GraphPad Instat software (GraphPad
Software Inc., San Diego, CA, USA), and the ManneWhitney
nonparametric test was conducted to determine the sta-
tistical significance, where appropriate. A p value < 0.05
was considered statistically significant.
Results
Effect of FIP-fve on AHR
To determine whether FIP-fve had a beneficial effect during
the inflammatory response in lungs, we evaluated the AHRFigure 5. (A) Th2 cytokines, (B) Th1 cytokines, and (C) TGF-b a
obtained from the normal control group and HDM sensitized/challe
the concentration of Th2 cytokines (IL-4, IL-5, and IL-13) in mice dec
Th1 cytokines (IFN-g and IL-12) increased after FIP-fve treatment. H
increase after treatment with FIP-fve, although there were no sig
TGF-b and BALF IL-10, respectively. The results are presented as me
immunomodulatory protein-Flammulina velutipes; HDM Z house d
TGF-b Z transforming growth factor beta; Th Z T helper.
Please cite this article in press as: Chu P-Y, et al., Oral fungal immun
monary inflammatory process and potential treatment for allergic airw
and Infection (2015), http://dx.doi.org/10.1016/j.jmii.2015.07.013in mice exposed to saline (vehicle control), mice exposed to
HDM, and mice exposed to HDM in addition to FIP-fve. The
mice that received FIP-fve during the sensitized phase
(pretreated) had a significantly lower AHR to methacholine
compared with the mice exposed to HDM tested at 20 mg/
mL level, and a similar response of inhibition of AHR was
observed in the mice that received FIP-fve in the challenge
phase (posttreated). The results indicated that FIP-fve
exerted a beneficial effect in reducing AHR in both pre-
or posttreated FIP-fve groups (Figure 2).Effect of FIP-fve on infiltrating cells of the lungs
It was obvious that increased cell numbers were induced in
the influx of total cells of the mice sensitized/challenged
by HDM (Figure 3A). These cellular populations consisted of
enhanced cell numbers of eosinophils and lymphocytes in
BALF compared with the normal control group, and reduced
in number as a result of oral FIP-fve treatment (in both
pretreated and posttreated groups; Figures 3B and 3C).
However, it could be seen that there was an increase in cell
numbers of monocytes in all groups (positive control, pre-
treated, and posttreated FIP-fve mice; Figure 3D). Thesend IL-10 in serum and BALF in different concentrations were
nged mice in the absence or presence FIP-fve treatment. In (A)
reased after FIP-fve treatment, and in (B) the concentration of
owever, in (C) the concentration of TGF-b and IL-10 tended to
nificant differences in PC and FIP-fve-treated groups in serum
ans  SEM. *p < 0.05. **p < 0.01. ***p < 0.001. FIP-fveZ fungal
ust mite; IL Z interleukin; SEM Z standard error of the mean;
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inflammatory responses in airways induced by HDM.
Effect of FIP-fve treatment on reversal of allergen-
induced airway inflammation and HDM-specific
antibodies in serum
Sensitization/challenge with HDM over a 4-week period
showed a statistically significant enhancement in HDM-
specific IgE, and IgG2a responses compared with the
normal control group (Figure 4). The oral FIP-fve treatment
(in both pre- and posttreated groups) showed a decreased
effect in serum IgE compared to the PC group (Figure 4A)
and an increased effect in serum IgG2a compared to the PC
group (Figure 4B). In short, FIP-fve treatment is capable of
inhibiting sensitization/challenge of HDM at the humoral
level as well.
Effect of FIP-fve treatment on cytokines in serum
and BALF
To investigate the effects of FIP-fve on cytokine regulation
in lung inflammation induced by HDM, we examined and
measured the cytokines from all groups of mice. After
sensitization/challenge with HDM, the production of IL-4,
IL-5, IL-10, IL-12, IL-13, and TGF-b in the serum and BALF
and IFN-g in the BALF of mice significantly increased
compared with that in the normal control group (Figure 5).
Meanwhile, the concentration of Th2 cytokines was dimin-
ished in pre- and posttreated FIP-fve groups, including IL-4,Figure 6. Effects of FIP-fve treatment on allergen-induced airw
tained and observed on Day 28 from the normal control group (NC)
(positive control group, PC), the pretreated FIP-fve group, and the p
and eosin; magnification, 100; internal scale marker, 100 mm. F
tipes; HDM Z house dust mite.
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(Figure 5A), whereas enhanced Th1 and Treg cytokines
including IFN-g, IL-12 (Figure 5B), and TGF-b, IL-10 pro-
duction also increased after treatment with FIP-fve in the
serum and BALF (Figure 5C).
Effect of FIP-fve on lung inflammation
The effect of the FIP-fve treatment in HDM-sensitized/
challenged mice on overall lung inflammation was evalu-
ated with hematoxylin and eosin staining, and histological
analysis revealed increased epithelial cell thicknesses and
numbers of inflammatory cell infiltrates compared with the
negative control group. In the pretreated and posttreated
FIP-fvemicemodels (Figure 6, Pretreat/Posttreat), therewas
significantly reduced inflammation compared with the mice
that received HDM (Figure 6, PC). The mice lung tissue sec-
tions were also evaluated for structural changes associated
with the airway remodeling. In both the pre-FIP (Figure 6,
Pretreat) and post-FIP (Figure 6, Posttreat) models of airway
inflammation, however, the FIP-fve treatment during the
sensitized/challenged phase of mice asthma model was
observed to lead to significantly decreased epithelial cell
thicknesses compared with PC mice.
Discussion
HDM is one of the predominant source of indoor allergens,
and there is increasing evidence that exposure to HDM in-
duces allergic events. The allergic lung inflammationay inflammations and remodeling. Mice lung tissues were ob-
and the HDM-treated mice in the absence of FIP-fve treatment
osttreated FIP-fve group, which were stained with hematoxylin
IP-fve Z fungal immunomodulatory protein-Flammulina velu-
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eosinophils and Th2 effector lymphocyte cells,23 and these
lines of evidence were also histopathologically confirmed by
mucous production and peribronchial inflammation in this
trial. A strongly growing amount of information on allergic
inflammation has been accumulated in numerous murine
allergic models, and most of them take steps to include
murine sensitization with OVA to simulate the pulmonary
inflammation condition. However, compared to sensitiza-
tion with OVA in murine models, HDM seems to be a more
ideal and realistic option to portray allergen-induced
allergic inflammation in the murine model, because of the
elicited tolerance to OVA when it was used without an
adjuvant. The administration of HDM to mice in the absence
of adjuvant not only addresses the tolerance problem, but
also offers a way to tackle strong inflammation.24 Sensiti-
zation to HDM in the murine model seems to be closer to
reality than using OVA. Our group has reported on the effect
of FIP-fve on allergic inflammation induced by OVA.21 As
opposed to the present study, the inflammatory responses
showed several differences between OVA and HDM.
Early reports demonstrated that oral administration of
FIP-fve during allergen sensitization induced a Th1-
predominant immune response.19 This study suggests that
FIP-fve has the ability to suppress the airway responsive-
ness that is a consequence of the structural changes that
occur, and as triggered by Th2 cytokines or IgE.
In the present study, both pre- and posttreatment with
FIP-fve exerted effects on AHR induced by methacholine in
mice sensitized/challenged with HDM. We observed a
marked attenuation of the level of inflammation in the
serum, BALF, and lung tissue. The results of histopatho-
logical analysis of the lungs demonstrated a suppressed
airway remodeling after the sensitized/challenged mice
received FIP-fve treatment. Infiltration of total cells, eop-
sinophils, and lymphocytes in the lungs showed a significant
drop in number compared with those in mice sensitized/
challenged with HDM alone.
We next evaluated the cytokines in BALF and serum. The
administration of FIP-fve showed its ability to stimulate the
proliferation of human peripheral blood mononuclear cells
with increasing IFN-g production.17,19 In this study, the
mice that received FIP-fve had a higher IFN-g production
compared with the mice sensitized/challenged with HDM
alone. Other reports25e27 indicated an increase in IFN-g,
which helped to inhibit the production of Th2 cytokines to
diminish the airway inflammation. The Th2 cytokine-IL-4 is
known to directly promote eosinophil infiltration, goblet
cell metaplasia, AHR, IgE production in serum, mastocy-
tosis, airway remodeling, and Th2 induction/mainte-
nance.21,22 Indeed, our results showed that HDM-sensitized
mice displayed higher IL-4 production compared with naı¨ve
mice and reduced IL-4 level after treatment with FIP-fve in
serum and BALF.
Moreover, an earlier study had shown that FIP-fve can
inhibit the IL-5-mediated survival of eosinophils through
the modulation of IL-5 R expression and apoptotic signal
protein production.28 FIP-fve had modulatory effects on
eosinophil apoptosis in vitro and eosinophil-related
allergic inflammation in vivo, which correlates with the
reduced eosinophil numbers in FIP-fve-treated mice in this
study.Please cite this article in press as: Chu P-Y, et al., Oral fungal immun
monary inflammatory process and potential treatment for allergic airw
and Infection (2015), http://dx.doi.org/10.1016/j.jmii.2015.07.013However, not all cytokines promote allergic airway dis-
eases. IL-10 and TGF-b have a suppressive effect on
inflammation response29e31 and belong to Treg cytokines.
We also found that TGF-b induced a significant increase in
BALF and serum from mice that were administered with
FIP-fve. According to previous reports,32e35 TGF-b is pro-
duced during AHR and asthma, and showed the effects of
negative feedback for allergic inflammation. IL-10 is an
important immunoregulatory cytokine in multiple biological
effects on different cells. A previous report indicated that
IL-10 helps to inhibit the production of IL-4 and -5 from Th2
cells.36 Other studies demonstrated that IL-10 has the
ability to inhibit eosinophil survival and IL-4-induced IgE
synthesis.37e39 In this study, IL-10 was highly expressed
both in serum and BALF in HDM-sensitized mice. Interest-
ingly, FIP-fve increased IL-10 production more compared to
mice sensitized/challenged with HDM although it did not
reach significant levels in groups treated with FIP-fve.
The allergen HDM is the most immunodominant allergen
involved in the production of HDM-specific IgE. In this work,
we demonstrated that immunization with HDM in mice re-
sults in a more significant enhancement of HDM-specific IgE
synthesis than in mice without HDM immunization. The
HDM-specific IgE was diminished after the FIP-fve treat-
ment (both pre- and posttreated groups). We therefore
concluded that FIP-fve had a beneficial effect of reducing
the allergy induced by HDM via decreasing the IgE synthesis.
In conclusion, this study demonstrates that oral FIP-fve
has an anti-inflammatory effect on HDM-induced airway
inflammations. In addition, these results suggest that FIP-
fve possesses a strong potential to be used as an alternative
therapy in food or pharmaceutical products being
commercially developed for allergic airway diseases such as
asthma. Most importantly, oral FIP-fve is easy to admin-
ister, which makes it an irreplaceable requirement for an
ideal treatment strategy.Conflicts of interest
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